Search research articles
Contact Us
Filters
Showing results (391-400 of 421) with videos related to
Page
of 43
Sort By:
Iscience
|
September 23, 2024
Single-cell sequencing reveals the heterogeneity of pancreatic neuroendocrine tumors under genomic instability and histological grading
Zeng Ye, Yan Zhou, Yuheng Hu, et al.
Gastroenterology
|
January 19, 2026
ENPP1-Regulated Extracellular Purine Metabolism Drives Pancreatitis-Mediated Pancreatic Cancer
Zhilong Ma, Mingwei Dong, Haoqi Pan, et al.
Cancer Letters
|
March 4, 2024
The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes
Zeng Ye, Qiang Li, Yuheng Hu, et al.
Cell Research
|
March 11, 2015
ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer
Shunrong Ji, Yi Qin, Si Shi, et al.
Cancer Cell
|
June 11, 2026
Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer
Rong Tang, Liquan Jin, Chen Chen, et al.
International Journal of Cancer
|
October 3, 2014
A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer
Liang Liu, Huaxiang Xu, Wenquan Wang, et al.
EMBO Molecular Medicine
|
July 17, 2013
A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth
Yuqing Zhang, Jingxuan Yang, Xiaobo Cui, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 30, 2022
Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)
Jiarui Li, Yuejuan Cheng, Chunmei Bai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2022
Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1-9]
Jiarui Li, Yuejuan Cheng, Chunmei Bai, et al.
Journal of Hepato-Biliary-Pancreatic Sciences
|
August 16, 2024
Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1)
Naohiro Okano, Manabu Kawai, Makoto Ueno, et al.
Page
of 43
Search research articles
Search
Showing results (391-400 of 421) with videos related to
Sort By:
Page
of 43
Iscience
|
September 23, 2024
Single-cell sequencing reveals the heterogeneity of pancreatic neuroendocrine tumors under genomic instability and histological grading
Zeng Ye, Yan Zhou, Yuheng Hu, et al.
Gastroenterology
|
January 19, 2026
ENPP1-Regulated Extracellular Purine Metabolism Drives Pancreatitis-Mediated Pancreatic Cancer
Zhilong Ma, Mingwei Dong, Haoqi Pan, et al.
Cancer Letters
|
March 4, 2024
The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes
Zeng Ye, Qiang Li, Yuheng Hu, et al.
Cell Research
|
March 11, 2015
ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer
Shunrong Ji, Yi Qin, Si Shi, et al.
Cancer Cell
|
June 11, 2026
Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer
Rong Tang, Liquan Jin, Chen Chen, et al.
International Journal of Cancer
|
October 3, 2014
A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer
Liang Liu, Huaxiang Xu, Wenquan Wang, et al.
EMBO Molecular Medicine
|
July 17, 2013
A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth
Yuqing Zhang, Jingxuan Yang, Xiaobo Cui, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 30, 2022
Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)
Jiarui Li, Yuejuan Cheng, Chunmei Bai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2022
Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1-9]
Jiarui Li, Yuejuan Cheng, Chunmei Bai, et al.
Journal of Hepato-Biliary-Pancreatic Sciences
|
August 16, 2024
Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1)
Naohiro Okano, Manabu Kawai, Makoto Ueno, et al.
Page
of 43